Online citations, reference lists, and bibliographies.
← Back to Search

Surgical And Medical Therapy For Malignant Pleural Mesothelioma

C. Cao
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma is a relatively rare but aggressive form of cancer arising from pleural mesothelial cells. Current medical therapy consists of pemetrexed-based chemoradiotherapy and radiotherapy alone. Additionally, a number of novel biological and immunotherapy agents are being developed. Surgical interventions can be categorized according to technique and intent. Selected patients with adequate cardiopulmonary reserve and resectable disease may achieve long-term survival from extrapleural pneumonectomy or extended pleurectomy/decortication in the context of multi-modality therapy. The present chapter presents the current evidence on medical and surgical management of malignant pleural mesothelioma based on data from systematic reviews.
This paper references
10.1200/JCO.1989.7.8.1157
Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.
P. Ruffié (1989)
10.1016/j.lungcan.2013.04.024
Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma.
C. Cao (2013)
10.1093/ejcts/ezr192
Long-term survival after lung-sparing total pleurectomy for locally advanced (International Mesothelioma Interest Group Stage T3-T4) non-sarcomatoid malignant pleural mesothelioma.
A. Nakas (2012)
10.1016/j.ejcts.2010.02.012
May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma?
T. Mineo (2010)
10.1016/J.ATHORACSUR.2007.06.066
Malignant pleural mesothelioma: surgical management in 285 patients.
P. Schipper (2008)
10.1016/j.lungcan.2009.08.019
Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy.
S. Boeluekbas (2011)
10.1016/J.JTCVS.2005.11.044
The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma.
J. Edwards (2006)
10.1200/JCO.2005.04.6813
Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.
W. Richards (2006)
10.1016/S1569-9293(02)00093-2
Malignant pleural mesothelioma: outcome of limited surgical management.
P. G. Phillips (2003)
10.1183/09031936.00039510
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
10.1038/bjc.2013.368
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
G. Ceresoli (2013)
10.1179/JOC.1996.8.2.159
Combined Chemotherapy in Pleurectomized Malignant Pleural Mesothelioma Patients
S. Hastürk (1996)
10.1016/j.ejcts.2009.04.044
Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies.
D. Trousse (2009)
How should we treat malignant pleural mesothelioma (MPM)?
L. Lampl (1999)
10.1016/j.jtcvs.2008.12.045
Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.
T. Yan (2009)
10.1016/j.jtcvs.2008.07.055
A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.
L. Zellos (2009)
10.1016/j.ejcts.2009.07.032
Three decades of experience in the surgical multi-modality management of pleural mesothelioma.
H. Luckraz (2010)
10.1097/JTO.0b013e31824ab6c5
Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma
L. Lang-Lazdunski (2012)
10.1378/CHEST.112.4_SUPPLEMENT.272S
Multimodality therapy for malignant pleural mesothelioma.
D. Sugarbaker (1997)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/S0169-5002(01)00257-4
Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma.
G. Ceresoli (2001)
10.1016/J.JTCVS.2006.03.068
Positron emission tomography predicts survival in malignant pleural mesothelioma.
R. Flores (2006)
10.3978/j.issn.2225-319X.2012.11.14
Radical pleurectomy and photodynamic therapy for malignant pleural mesothelioma.
J. Friedberg (2012)
10.1067/MTC.2002.125817
Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma.
T. T. Lee (2002)
Pleurectomy/decortication plus chemotherapy: outcomes of 40 cases of malignant pleural mesothelioma.
F. Colaut (2004)
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.3978/j.issn.2225-319X.2012.11.07
Systematic review of trimodality therapy for patients with malignant pleural mesothelioma.
C. Cao (2012)
10.3978/j.issn.2225-319X.2012.10.05
Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future.
A. Nowak (2012)
10.1016/S1010-7940(03)00376-2
Treatment of mesothelioma in Bloemfontein, South Africa.
W. de Vries (2003)
10.1097/JTO.0b013e3182199819
Intensity-Modulated Radiotherapy After Extrapleural Pneumonectomy in the Combined-Modality Treatment of Malignant Pleural Mesothelioma
A. Chi (2011)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.1016/J.EJSO.2004.08.014
Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma.
J. Halstead (2005)
10.3978/j.issn.2225-319X.2012.11.04
Malignant pleural mesothelioma: an epidemiological perspective.
Benjamin M. Robinson (2012)
10.1097/JTO.0b013e3181ed0489
A Systematic Review of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
C. Cao (2010)
10.1016/j.athoracsur.2010.04.110
Characteristics of malignant pleural mesothelioma in women.
A. Wolf (2010)
10.1002/JSO.2930600207
Optimal management of malignant mesothelioma after subtotal pleurectomy: Revisiting the role of intrapleural chemotherapy and postoperative radiation
E. Sauter (1995)
10.1016/S1470-2045(11)70307-2
The MARS feasibility trial: conclusions not supported by data.
W. Weder (2011)
10.1002/jso.21261
Symptomatic and quality of life changes after extrapleural pneumonectomy for malignant pleural mesothelioma
V. Ambrogi (2009)
10.1016/S1010-7940(02)00273-7
The management of malignant pleural mesothelioma; single centre experience in 10 years.
T. Aziz (2002)
10.1510/ICVTS.2007.166322
Radical surgery for malignant pleural mesothelioma: results and prognosis.
M. Okada (2008)
10.1245/s10434-011-1728-x
Summary of Prognostic Factors and Patient Selection for Extrapleural Pneumonectomy in the Treatment of Malignant Pleural Mesothelioma
Christopher Cao (2011)
Malignant pleural mesothelioma. Extrapleural pneumonectomy and pleurectomy.
K. Allen (1994)
10.1016/j.athoracsur.2009.05.036
Trimodality therapy for malignant pleural mesothelioma.
G. Buduhan (2009)
10.1016/j.ijsu.2008.04.004
Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
S. Neragi-Miandoab (2008)
10.1200/JCO.2008.19.8523
Malignant pleural mesothelioma.
A. Tsao (2009)
10.1510/icvts.2009.223255
Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything?
M. Lucchi (2010)
10.1016/j.lungcan.2008.01.013
Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes.
K. Ribi (2008)
10.1016/J.JTCVS.2005.02.051
Importance of mediastinoscopy, bilateral thoracoscopy, and laparoscopy in correct staging of malignant mesothelioma before extrapleural pneumonectomy.
J. Alvarez (2005)
10.1016/j.jtcvs.2012.12.037
Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.
D. Sugarbaker (2013)
10.1016/j.radonc.2011.09.025
Adjuvant radiotherapy after extrapleural pneumonectomy for mesothelioma. Prospective analysis of a multi-institutional series.
S. Tonoli (2011)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1016/j.athoracsur.2009.01.026
Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma.
T. Yan (2009)
10.3978/j.issn.2225-319X.2012.10.03
Mesothelin-targeted immunotherapies for malignant pleural mesothelioma.
Jonathan Villena-Vargas (2012)
10.5761/ATCS.OA.10.01572
Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience.
T. Yan (2011)
10.1016/j.ijrobp.2011.09.027
Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.
K. Rosenzweig (2012)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1016/J.LUNGCAN.2007.02.004
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
F. Rea (2007)
10.1016/J.EJCTS.2007.09.039
The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma.
A. Nakas (2008)
10.1016/j.athoracsur.2009.05.022
Endoscopic ultrasound-guided fine needle aspiration for staging of malignant pleural mesothelioma.
D. Rice (2009)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1016/S1556-0864(15)31536-7
Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma.
D. Sugarbaker (2006)
10.1200/JCO.2008.17.5604
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
10.1016/S1010-7940(96)01008-1
Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery.
O. Soysal (1997)
10.3978/j.issn.2225-319X.2012.11.13
Extrapleural pneumonectomy and extended pleurectomy/decortication for malignant pleural mesothelioma: the Memorial Sloan-Kettering Cancer Center approach.
V. Rusch (2012)
10.1002/JSO.2930600410
Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: The ucla experience
J. D. Lee (1995)
10.1097/JTO.0b013e3182208e3f
Recommendations for Uniform Definitions of Surgical Techniques for Malignant Pleural Mesothelioma: A Consensus Report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group
D. Rice (2011)
10.1016/j.jtcvs.2009.02.028
Venous thromboembolism in patients receiving multimodality therapy for thoracic malignancies.
A. Patel (2009)
10.1016/j.lungcan.2011.12.009
Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure.
O. Rena (2012)
10.1016/S0022-5223(98)70274-0
Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.
H. Pass (1998)
10.1038/bjc.2013.514
The latency period of mesothelioma among a cohort of British asbestos workers (1978–2005)
G. Frost (2013)
10.1002/1097-0142(197503)35:3<734::AID-CNCR2820350328>3.0.CO;2-N
Indications for pleurectomy in malignant effusion
N. Martini (1975)
10.1097/JTO.0b013e3181b7d470
The Mars trial: resolution of the surgical controversies in mesothelioma?
V. Rusch (2009)
10.1158/1078-0432.CCR-10-2275
Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers
R. Hassan (2010)
10.1016/S1010-7940(01)00995-2
Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control.
A. Martin-Ucar (2001)
10.3978/j.issn.2225-319X.2012.10.07
Novel radiation therapy approaches in malignant pleural mesothelioma.
A. Rimner (2012)
10.1007/BF02306613
Surgically debulked malignant pleural mesothelioma: Results and prognostic factors
H. Pass (2006)
10.1016/J.EJCTS.2007.01.061
Right extrapleural pneumonectomy for malignant mesothelioma via median sternotomy or thoracotomy? Short- and long-term results.
J. Edwards (2007)
10.1016/S0003-4975(99)01038-3
Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.
V. Rusch (1999)
10.1016/j.jtcvs.2009.02.046
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.
T. R. Tilleman (2009)
10.1177/030089169608200111
Surgery Followed by Intracavitary plus Systemic Chemotherapy in Malignant Pleural Mesothelioma
M. Colleoni (1996)



Semantic Scholar Logo Some data provided by SemanticScholar